HELSINKI, Finland, October 2021. Finnish bioinformatics software company Euformatics, which develops and sells world-leading NGS interpretation and quality control tools, has announced a distributor partnership with All Eights covering the Malaysian market.
The agreement marks an important milestone for the Finland-based company as the announcement surpasses its goal of signing agreements with at least 1 new distributor partner per month in 2021. The agreement with Singapore-headquartered company All Eights covers the Malaysian division of its operations, and includes the full omnomics Suite of products from Euformatics including the best-in-class real-time sample quality control software, omnomicsQ, as well as the comprehensive variant interpretation and reporting tool, omnomicsNGS.
All Eights has a successful history going back to its founding in 1983 providing in-vitro clinical diagnostic and research tools to customers in Singapore and has since expanded its operations to include neighbouring Malaysia. Its mission to “provide clinical laboratories with high quality, innovative products to improve their current workflow and systems” positions it well with Euformatics drive to accelerate the transition to precision medicine, and its strong application specialist team enables the company to provide high quality training and support to its customers.
“We were looking for a software solution to enable our customers in Malaysia to improve their NGS testing capabilities”, said Yi-Tee Lim, Managing Director at All Eights. “NGS is growing at a strong rate all around the world and Malaysia is no exception. We are impressed with the user-friendliness of omnomicsNGS and its ability to reduce the time it takes to analyse a clinical sample really resonates with us and our mission. We believe that the tools from Euformatics will make a real positive impact on the way NGS is used in Malaysia and are exactly what our customers are looking for to expand their testing capabilities in the coming years”, he added.
Euformatics CEO, Tommi Kaasalainen, commented that “Having lived and studied in Kuala Lumpur, Malaysia has a special place in my heart and that is why this agreement is of particular importance to me personally. We have made it our goal to bring our products particularly to Southeast Asia this year, and this agreement with All Eights gives us a very clear avenue for achieving that goal. We have already been impressed with the level of knowledge and expertise in NGS at All Eights and believe that together we will have great success in the market. It is clear to us that countries like Malaysia are the key areas to focus on as NGS uptake continues at an unprecedented rate; with its growing population and need for quality healthcare, NGS is fast becoming an essential technology for clinical diagnostics.”
The agreement adds to the list of announcements from Euformatics since the beginning of 2021, as the company now has distribution partners in Latin America, Europe, the Middle East and Asia. CEO Tommi Kaasalainen has made international growth a key target for the company in the coming years and these agreements show the strong progress that has already been made.
About All Eights:
All Eights is a distributor for in vitro diagnostic products in Malaysia, Singapore, and Brunei founded in 1983. Through the years, All Eights has nurtured close relationships with its customers in healthcare settings and laboratories. Whether in clinical diagnostics or bioresearch, All Eights is dedicated to providing innovative and high-quality products suitable for its local customers to improve their existing workflows and performance. With close to 30 highly trained technical support staff attending to our installation’s base of more than 500 instruments, we are committed to providing excellent after sales services to our customers.
Visit our website www.alleights.com.my for more information and follow us @alleights.malaysia on Instagram and find us @All Eights (Malaysia) Sdn Bhd on LinkedIn.
About Euformatics:
Euformatics is a Finnish software company that specialises in high standard bioinformatics tools for genomic data interpretation. Since 2010, Euformatics has been helping medical doctors and molecular genetics laboratories provide better precision medicine for cancer, common or rare disease diagnostics. At present, our core solution is the omnomics Suite which includes omnomicsNGS; for clinical analysis and reporting of patient NGS data, and omnomicsQ; for NGS data quality management.
For more information, please visit our website www.euformatics.com
Press relations:
Jamie McDonald
Euformatics
jamie.mcdonald@euformatics.com
Shanna Tam
All Eights
shanna@alleight.com